Benjamin A. Weinberg, MD, presents the case of a 35-year-old man with oligometastatic disease, and the panel provides insights on treatment decisions.
FDA to Hold End-of-Phase 2 Meeting for Botensilimab Plus Balstilimab in R/R mCRC
Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin Lymphoma
Salvage Nivolumab/Ipilimumab Following Nivolumab Affords Treatment-Free Survival in RCC
Gutierrez and Leslie Discuss Recent Efforts and Future Advances in CAR T-Cell Therapy
Pooled Analysis Shows Cytoreduction to Be Safe, Tolerable in Younger Patients With PV
FDA Approves Noninvasive Stool RNA Screening Test for CRC
Dr Liu Previews ASCO 2024 Lung Cancer Data
Dr Rajkumar Previews ASCO 2024 Data in Multiple Myeloma
Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer
Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer